Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| XBiotech Inc.XBIT · Entity 7044 | Director · Chief Executive Officer · 10% owner | March 17, 2025 | March 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
XBiotech Inc.
Report date March 17, 2025 · Filed March 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.52 · Expires 2035-03-16 | Direct | 1,896,609 |
Reported balance
After 2025-03-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-17 · Grant · Acquired 1,026,228 · Balance 1,896,609 F1: On March 17, 2025 (the Grant Date) John Simard was granted nonstatutory stock options under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock at an exercise price equal to the closing price of the Company's common stock, as reported by the Nasdaq Stock Market, on the Grant Date. The options vested immediately on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 17, 2025 (the Grant Date) John Simard was granted nonstatutory stock options under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock at an exercise price equal to the closing price of the Company's common stock, as reported by the Nasdaq Stock Market, on the Grant Date. The options vested immediately on the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 19, 2025 15:03 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 1,026,228 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0000950170-25-041946 · ownership.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,896,609 Underlying: Common Stock · 1,026,228 shares Expires 2035-03-16 F1 · security: On March 17, 2025 (the Grant Date) John Simard was granted nonstatutory stock options under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock at an exercise price equal to the closing price of the Company's common stock, as reported by the Nasdaq Stock Market, on the Grant Date. The options vested immediately on the Grant Date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | XBiotech Inc. XBIT · Entity 7044 | OtherConvertible Loan Agreement · Derivative | 2,470,355 | $10,000,000.00 Strike: $4.05 | $24,703,550,000,000.00 |
DisclosureSEC source: 0000950170-25-013647 · ownership.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 870,381 Underlying: Common Shares or Preferred Shares · 2,470,335 shares Expires 2029-01-03 F1 · shares: On January 31, 2025, the Convertible Loan Agreement (the "Loan") dated as of January 3, 2024 between XBiotech Inc. and John Simard, the Company's Founder, President, Chief Executive Officer, and Chairman, was terminated upon full repayment of the Loan by the Company. As a result, all conversion rights to XBiotech stock associated with the Loan were extinguished. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 10:48 UTC | XBiotech Inc. XBIT · Entity 7044 | PurchaseConvertible Loan Agreement · Derivative | 2,470,355 | $10,000,000.00 Strike: $4.05 | $24,703,550,000,000.00 |
DisclosureSEC source: 0000950170-24-002316 · ownership.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,840,736 Underlying: Common Shares or Preferred Shares · 2,470,355 shares Expires 2029-01-03 F1 · shares: On January 3, 2024, XBiotech Inc. ("XBiotech" or the "Company") entered into a Convertible Loan Agreement (the "Loan") with John Simard, the Company's Founder, President, Chief Executive Officer and Chairman. The Loan provides $10 million in immediate funding for the construction of a new, state-of-the-art research and development facility at 5217 Winnebago Lane in Austin, Texas. The Loan is secured by the real estate and cash holdings of the Company, with interest to accrue at a simple rate equal to eight percent per year and interest-only payments to be made at six - month intervals after the Loan is funded. At Mr. Simard's election, the balance may be converted to XBiotech stock at any time the Loan balance is outstanding at a fixed conversion price equal to the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of this Agreement, which is $4.048 per share. Continued in Remarks. F2 · derivative.underlying_shares: As of the filing date of this Form 4, Mr. Simard could obtain up to 2,470,355 XBiotech common or preferred shares by converting the full $10,000,000 Loan balance at the conversion price of $4.048 per share. The total number of shares exercisable under the Loan could fluctuate based on Mr. Simard' cumulative stock ownership and the total number of XBiotech shares outstanding. F3 · balance_after: This figure is derived by adding the 2,470,355 shares that Mr. Simard could obtain by converting the Loan balance as of the filing date of this Form 4 to the 1,370,381 stock options Mr. Simard holds as previously disclosed in XBiotech's April 28, 2023 Schedule 14A. As stated in footnote 2 above, the total number of shares exercisable under the Loan could fluctuate based on Mr. Simard' cumulative stock ownership and the total number of XBiotech shares outstanding. Read SEC document |
| October 18, 2021 Filed Feb 15, 2022 16:05 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 33,000 | $13.07 | $431,253.90 |
DisclosureSEC source: 0001209191-22-009745 · doc4.xml · nonDerivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,823,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 15, 2021 Filed Feb 15, 2022 16:05 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 17,000 | $13.32 | $226,470.60 |
DisclosureSEC source: 0001209191-22-009745 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,856,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 12:26 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 21,125 | $12.90 | $272,523.06 |
DisclosureSEC source: 0001209191-21-060523 · doc4.xml · nonDerivative · entry 4 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,873,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 12:26 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 10,875 | $12.83 | $139,526.25 |
DisclosureSEC source: 0001209191-21-060523 · doc4.xml · nonDerivative · entry 3 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,962,452 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 12, 2021 Filed Oct 15, 2021 12:26 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 18,000 | $12.77 | $229,939.20 |
DisclosureSEC source: 0001209191-21-060523 · doc4.xml · nonDerivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,973,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 07, 2021 Filed Oct 15, 2021 12:26 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 39,286 | $12.45 | $489,110.70 |
DisclosureSEC source: 0001209191-21-060523 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,923,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 06, 2021 Filed Oct 6, 2021 17:48 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 10,714 | $12.53 | $134,259.28 |
DisclosureSEC source: 0001209191-21-059849 · doc4.xml · nonDerivative · entry 3 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,962,452 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 17:48 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 14,218 | $12.66 | $180,058.17 |
DisclosureSEC source: 0001209191-21-059849 · doc4.xml · nonDerivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,973,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 17:48 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 23,681 | $13.08 | $309,863.52 |
DisclosureSEC source: 0001209191-21-059849 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,987,384 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 16:39 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 19,684 | $13.23 | $260,488.21 |
DisclosureSEC source: 0001209191-21-058475 · doc4.xml · nonDerivative · entry 4 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,011,065 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 16:39 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 18,558 | $13.07 | $242,463.98 |
DisclosureSEC source: 0001209191-21-058475 · doc4.xml · nonDerivative · entry 3 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,030,749 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 16:39 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 16,396 | $13.41 | $219,801.50 |
DisclosureSEC source: 0001209191-21-058475 · doc4.xml · nonDerivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,049,307 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 28, 2021 Filed Oct 1, 2021 16:39 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 6,263 | $14.27 | $89,363.62 |
DisclosureSEC source: 0001209191-21-058475 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,065,703 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 10:59 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 29,890 | $14.81 | $442,790.46 |
DisclosureSEC source: 0001209191-21-057877 · doc4.xml · nonDerivative · entry 3 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,071,966 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 10:59 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 11,418 | $14.49 | $165,409.14 |
DisclosureSEC source: 0001209191-21-057877 · doc4.xml · nonDerivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,101,856 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 10:59 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 9,892 | $14.68 | $145,219.51 |
DisclosureSEC source: 0001209191-21-057877 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,113,274 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 22, 2021 Filed Sep 22, 2021 18:12 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 19,669 | $15.14 | $297,757.19 |
DisclosureSEC source: 0001209191-21-057295 · doc4.xml · nonDerivative · entry 3 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,123,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 18:12 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 16,860 | $15.24 | $256,912.68 |
DisclosureSEC source: 0001209191-21-057295 · doc4.xml · nonDerivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,142,835 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 18:12 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 13,471 | $15.06 | $202,913.67 |
DisclosureSEC source: 0001209191-21-057295 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,159,695 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 14, 2021 Filed Jul 19, 2021 14:27 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 50,000 | $18.15 | $907,350.00 |
DisclosureSEC source: 0001209191-21-047105 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,173,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 22, 2021 Filed Mar 22, 2021 14:20 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock options · Derivative | 500,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-21-022278 · doc4.xml · derivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stocks · 500,000 shares Expires 2021-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2021 Filed Mar 22, 2021 14:20 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionCommon Shares | 500,000 | $7.50 | $3,750,000.00 |
DisclosureSEC source: 0001209191-21-022278 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,223,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 11:01 UTC | XBiotech Inc. XBIT · Entity 7044 | OtherStock Options · Derivative | 500,000 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-21-006384 · doc4.xml · derivative · entry 5 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-12-06 Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 11:01 UTC | XBiotech Inc. XBIT · Entity 7044 | OtherStock Options · Derivative | 150,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0001209191-21-006384 · doc4.xml · derivative · entry 4 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-06-27 Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 11:01 UTC | XBiotech Inc. XBIT · Entity 7044 | OtherStock Options · Derivative | 89,260 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-21-006384 · doc4.xml · derivative · entry 3 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,740 Underlying: Common Stock · 89,260 shares Expires 2028-06-19 Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 11:01 UTC | XBiotech Inc. XBIT · Entity 7044 | OtherStock Options · Derivative | 13,484 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001209191-21-006384 · doc4.xml · derivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,516 Underlying: Common Stock · 13,484 shares Expires 2027-06-19 Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 11:01 UTC | XBiotech Inc. XBIT · Entity 7044 | OtherStock Options · Derivative | 1,875 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001209191-21-006384 · doc4.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,125 Underlying: Common Stock · 1,875 shares Expires 2026-03-31 Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 17:07 UTC | XBiotech Inc. XBIT · Entity 7044 | OtherCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-051306 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,723,166 F1 · price: Shares transferred pursuant to obligation Read SEC document |
| August 27, 2020 Filed Sep 1, 2020 16:05 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0001209191-20-048900 · doc4.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-08-27 Read SEC document |
| August 27, 2020 Filed Apr 27, 2021 17:33 UTC Amendment | XBiotech Inc. XBIT · Entity 7044 | GrantStock Options · Derivative | 0 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0001209191-21-028625 · doc4a.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2030-08-27 Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 16:48 UTC | XBiotech Inc. XBIT · Entity 7044 | Disposition to issuerCommon Stock | 2,016,466 | $30.00 | $60,493,980.00 |
DisclosureSEC source: 0001209191-20-009272 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,310,594 Read SEC document |
| February 12, 2020 Filed Mar 19, 2020 13:29 UTC Amendment | XBiotech Inc. XBIT · Entity 7044 | Disposition to issuerCommon Stock | 2,103,894 | $30.00 | $63,116,820.00 |
DisclosureSEC source: 0001209191-20-020220 · doc4a.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,223,166 Read SEC document |
| December 06, 2019 Filed Dec 11, 2019 15:52 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 1,000,000 | $11.12 Strike: $11.12 | $11,120,000.00 |
DisclosureSEC source: 0001209191-19-060015 · doc4.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625,000 Underlying: Common Stock · 1,000,000 shares Expires 2029-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On December 6, 2019 (the Grant Date) John Simard was granted nonstatutory stock options under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock at an exercise price equal to the closing price of the Company's common stock, as reported by the Nasdaq Stock Market, on the Grant Date. The options will vest in two equal installments on the six-month anniversary and the first anniversary of the Grant Date. F1 · derivative.exercise_price: On December 6, 2019 (the Grant Date) John Simard was granted nonstatutory stock options under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock at an exercise price equal to the closing price of the Company's common stock, as reported by the Nasdaq Stock Market, on the Grant Date. The options will vest in two equal installments on the six-month anniversary and the first anniversary of the Grant Date. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 17:24 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 300,000 | $7.45 Strike: $7.45 | $2,235,000.00 |
DisclosureSEC source: 0001209191-19-039527 · doc4.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On June 27, 2019 (the Grant Date) John Simard was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purcahse shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The options vest in three equal annual installments commencing as of the first anniversary of the Grant Date with an expiry of ten years from the Grant Date. F1 · derivative.exercise_price: On June 27, 2019 (the Grant Date) John Simard was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purcahse shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The options vest in three equal annual installments commencing as of the first anniversary of the Grant Date with an expiry of ten years from the Grant Date. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 11:00 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 50,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-18-063616 · doc4.xml · derivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 11:00 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionCommon Stock | 50,000 | $2.50 | $125,000.00 |
DisclosureSEC source: 0001209191-18-063616 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,327,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2018 Filed Oct 12, 2018 15:00 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-18-054878 · doc4.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-28 Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 15:13 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-18-038901 · doc4.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-06-19 Read SEC document |
| June 19, 2017 Filed Jun 23, 2017 14:54 UTC Amendment | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 75,000 | $4.24 Strike: $4.24 | $318,000.00 |
DisclosureSEC source: 0001209191-17-041618 · doc4a.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2017 Filed Jun 23, 2017 14:17 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 75,000 | $4.24 Strike: $4.24 | $318,000.00 |
DisclosureSEC source: 0001209191-17-041609 · doc4.xml · derivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On September 14, 2016 (the Grant Date) Fabrizio Bonanni was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purcahse shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market, with an expiry of ten years from the Grant Date. Half of the Options vest on December 20, 2016 and another half of the Options vest on June 20, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 17:12 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 240,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001209191-17-035497 · doc4.xml · derivative · entry 3 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires 2017-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Options granted on June 15, 2007 with a strike price of $1.25 CAD, which was converted to $0.9317 USD using an exchange rate of 0.7454. Read SEC document |
| May 24, 2017 Filed May 25, 2017 17:12 UTC | XBiotech Inc. XBIT · Entity 7044 | Tax withholdingCommon Stock | 116,207 | $8.17 | $949,411.19 |
DisclosureSEC source: 0001209191-17-035497 · doc4.xml · nonDerivative · entry 2 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,277,060 F2 · kind: Due to the options expiring on June 15, 2017, Mr. Simard agreed to exercise these options through the "net exercise" method on May 24, 2017. Mr. Simard received 123,793 shares of common stock on a net exercise to purchase 240,000 shares of common stock. Mr. Simard forfeited 116,207 shares of common stock underlying the option in payment of the exercise price and associated taxes, using the closing stock price on May 24, 2017 of $8.17. Read SEC document |
| May 24, 2017 Filed May 25, 2017 17:12 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionCommon Stock | 240,000 | $0.93 | $223,608.00 |
DisclosureSEC source: 0001209191-17-035497 · doc4.xml · nonDerivative · entry 1 SIMARD JOHN · CIK 0001639078 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,393,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Options granted on June 15, 2007 with a strike price of $1.25 CAD, which was converted to $0.9317 USD using an exchange rate of 0.7454. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.